Charenton Le Pont

Researchers are studying adults with moderate to severe Systemic Lupus Erythematosus (SLE) to understand the risks of developing malignancies and serious infections when treated with anifrolumab compared to those receiving standard care without anifrolumab. This observational study aims to provide safety data about these risks in real-world settings. Participants prescribed anifrolumab according to local medical practice will be observed and compared with similar patients who do not start anifrolumab treatment. The study tracks outcomes such as new malignancies, serious infections, infections leading to hospitalization, and infection-related deaths over several years, with follow-up for malignancies up to November 2031 and infections up to November 2027. Throughout the study, researchers will collect data on participants for at least 12 months before starting anifrolumab and during the observation period to monitor health events. Key outcome measures include the occurrence of malignancies and serious infections. The study includes adults aged 18 years and older with documented moderate to severe SLE activity, ensuring careful safety monitoring over an extended timeline.

Colorectal cancer prevention relies on detecting and removing precursor lesions during colonoscopy. This research evaluates how a structured digital training program called Colo-ID affects the accuracy of predicting the histology of colorectal polyps using optical diagnosis. The study is prospective, observational, and takes place in a real-life clinical setting at a single center, focusing on adult patients with detected polyps during routine colonoscopy. The intervention involves endoscopists completing the Colo-ID digital training, which provides education on optical polyp characterization through image-based learning and simulated performance assessments. During colonoscopy procedures, optical predictions of polyp histology are recorded using standard imaging methods. All polyps are resected and sent for standard histopathological analysis. The study compares prediction accuracy before and after the training program without altering patient management. Participants are adults undergoing colonoscopy with at least one polyp detected. Researchers collect data on optical histology predictions and corresponding histopathology results. They measure concordance between these predictions and pathology findings as the primary outcome. Secondary outcomes include diagnostic accuracy metrics and performance differences based on polyp size and location. Data is collected between February and June 2026, with no extra risk to patients as care follows usual clinical practice.

Researchers are studying the use of high-performance computer-aided diagnosis (CAD) systems designed to detect colorectal lesions during screening colonoscopy. The trial aims to evaluate whether using CAD can reduce the risk of advanced adenomas or interval cancers developing between colonoscopies over a three-year period. This study is particularly focused on patients undergoing colonoscopy screening due to positive immunological tests or personal and family histories related to colorectal cancer and polyps. Participants will be randomly assigned to one of two groups after confirming proper colonoscopy conditions: one group will receive a standard colonoscopy without computer assistance, and the other will have a colonoscopy using a CAD system (either CAD EYE or GENIUS). After the initial procedure, patients will have a follow-up consultation one month later to receive histological results. At three years, all patients at high risk will undergo another colonoscopy using the CAD system, performed by a different blinded investigator. Low-risk patients will have routine care follow-up, including colonoscopies outside the study protocol. During the study, researchers will collect colonoscopy results and follow patients to monitor the occurrence of advanced adenomas over 36 months. Assessments include the quality of bowel preparation, colonoscopy completion, and histological findings. The study includes safety and efficacy follow-up visits, and data from both initial and follow-up colonoscopies will be evaluated to assess the impact of CAD systems on colorectal cancer prevention.

The emergence of extended-spectrum beta-lactamase-producing Enterobacteriaceae (E-ESBL) is an important public health concern, especially in children with urinary tract infections (UTIs). These bacteria can lead to increased use of penem antibiotics, which may cause resistant strains. This study evaluates the effects of different antibiotic treatments on the presence of E-ESBL in the digestive tract of children aged 3 months to under 3 years who have febrile UTIs. The goal is to compare the impact of intravenous amikacin versus intravenous or intramuscular ceftriaxone or oral cefixime on the emergence of these bacteria in stools. Participants receive one of the antibiotic treatments as monotherapy: amikacin given intravenously, ceftriaxone administered either intravenously or intramuscularly, or cefixime taken orally. Before starting treatment, an anorectal swab is collected to check for E-ESBL bacteria, and a second swab is taken three to four days after beginning the antibiotic therapy to monitor any changes. During the study, children are monitored for the presence of E-ESBL in their stools on day 4 through these swabs. Parents provide consent and confirm their understanding of the study information. The study measures the bacterial carriage in the digestive tract after treatment and ensures safety by excluding children currently hospitalized or on multiple antibiotics. The participation duration aligns with the timing of these assessments.